PPBT Purple Biotech Ltd: Earnings per share for the trailing year
The EPS growth rate over the last 12 months YoY demonstrates profit dynamics, where the latest parameter stands at -151.40. Purple Biotech (PPBT) develops agents to combat tumor resistance in complex cases. Antibody production is outsourced to external centers in Europe and the US. The asset value is not tied to current prices but is based on the results of clinical trials.
%20Purple%20Biotech%20Ltd.&width=1200&height=400&colorIndex=0&v=mwg3sw3k.w4s-7di3ke8&start=20220704&end=20261114&filename=GURU_Markets_-_PPBT_-_Purple-Biotech_-_Net-earnings-per-share-EPS-TTM "PPBT (Purple Biotech) Net earnings per one share for the last twelve months history from 02/11/2024 to 11/14/2026 | 👁️GURU.Markets👁️")
PPBT (Purple Biotech): analytical breakdowns and indicator data
- current quotes and average value forecast:
- company stock capitalization data:
- issuer book value statistics:
- company total debt and liquidity indicators:
Total Debt to Capital Purple Biotech|PPBT - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital purple-biotech.com|PPBT - Company Debts|Debts to Book Capitalization Ratio Kitov Pharma|PPBT - Company Long-Term Debt|Company Short-Term Debt Purple Biotech|Immediate Liquidity purple-biotech.com
- net income and valuation ratios data:
PPBT - Net Income|Expected Net Income Purple Biotech|PPBT - P/E Multiple|Future Price to Earnings Purple Biotech Corp|PPBT - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Kitov Pharma|PPBT - Profit before payment of interest, taxes and amortization|Net earnings per one share for the last twelve months Purple Biotech|PPBT - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months purple-biotech.com|PPBT - Earnings growth in current year|Expected net earnings per share growth next year Purple Biotech
- revenue and sales details:
Initial company analysis:Purple Biotech Ltd
This indicator serves as a fundamental tool for assessing the efficiency of earnings per share generation. It measures the percentage change in net income over a rolling year, capturing the dynamics of the business's real profitability. By analyzing the historical delta of EPS YoY TTM, an investor determines the company's ability to scale profits. For Purple Biotech (PPBT), this growth confirms the commercial success of developing combined onco-immunological therapies. The positive trend here signals growing physician confidence in new methods of fighting cancer.
Competitor analysis
Earnings per share for the trailing year ONC (BeiGene)|Halozyme Inc. (HALO) - Earnings per share for the last twelve months|RevMed - Earnings per share for the trailing year|AAPG (Ascentage Pharma Group International) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months CG Oncology, Inc. CGON|Net earnings per share for the last 12 months URGN (urogen.com)|Earnings per share for the last twelve months BCAX (Bicara Therapeutics)|Net earnings per share (EPS TTM) PSNL (personalis.com)|Earnings per share for the trailing year ERAS|DCTH - Earnings per share for the last twelve months|Y-mAbs Therapeutics (YMAB) - Net earnings per share for the last 12 months|AURA: Net earnings per share (EPS TTM)|Earnings per share for the last 12 months CADL|Earnings per share for the last twelve months Accuray Inc.|SELLAS Life Sciences Group (SLS) - Net earnings per share for the last four quarters|Net earnings per share for the last 12 months ACTU (Actuate Therapeutics, Inc)|Net earnings per share for the last four quarters Citius Oncology|TuHURA Biosciences, Inc. - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Protara TARA|fatetherapeutics.com - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Aadi Bioscience|TCRX: Net earnings per share (EPS TTM)|CSBR - Net earnings per share for the last four quarters|XBIT (XBiotech) - Net earnings per share (EPS TTM)|CVM: Earnings per share for the trailing year|Net earnings per share (EPS TTM) OSTX|RADX (Radiopharm Theranostics Limited) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) ARTV (Artiva Biotherapeutics, Inc.)|Earnings per share for the trailing year ANL|VERU: Net earnings per share for the last 12 months|TPST - Net earnings per share (EPS TTM)|XLO (xiliotx.com) - Net earnings per share for the last 12 months|Renovaro Biosciences - Earnings per share for the trailing year|Net earnings per share for the last 12 months MURA|Earnings per share for the last twelve months KAPA|Net earnings per share for the last 12 months OKUR (OnKure Therapeutics Inc)|Net earnings per share (EPS TTM) CytoMed (GDTC)|Earnings per share for the last twelve months curis.com CRIS|APLM (Apollomics, Inc.) - Earnings per one share for the last 12 months|Tharimmune Corporation - Net earnings per share (EPS TTM)|ADVB (advanbiomed.com) - Earnings per share for the last 12 months|Genprex, Inc (GNPX) - Earnings per share for the last twelve months|CLDI: Earnings per share for the last four quarters|SBFM (Sunshine Biopharma, Inc.) - Net earnings per share (EPS TTM)|Earnings per share for the last 12 months XBIO (Xenetic Biosciences)|Net earnings per share (EPS TTM) SLRX|Earnings per share for the last four quarters AONC|Earnings per share for the last twelve months BeiGene BGNE|CKPT - Net earnings per share for the last 12 months|elevationoncology.com - Net earnings per share (EPS TTM)|Earnings per share for the trailing year ICAD (icadmed.com)|IKNA: Net earnings per share (EPS TTM)|Earnings per share for the last 12 months NTBL|VIRX (viracta.com) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months MorphoSys Inc MOR|Earnings per share for the last twelve months NAYA Bio (NAYA)|AAPGV: Earnings per one share for the last 12 months
